REG - Futura Medical PLC - MED3000, Eroxon® UK Launch

Futura MedicalAnnouncement

18/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230418:nRSR4464Wa&default-theme=true

RNS Number : 4464W  Futura Medical PLC  18 April 2023

 

18 April 2023

 Futura Medical plc

("Futura" or the "Company")

MED3000, Eroxon® UK Launch

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical
company developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys® drug delivery technology currently focused
on sexual health, today announces that its breakthrough, topical gel
formulation for the treatment of erectile dysfunction (ED), MED3000, under the
brand name Eroxon®, is now available for purchase in the UK.

Futura's EU and UK distribution partner, Cooper Consumer Health, a leading
International independent self-care organisation, has today announced that
Eroxon® is now available from boots.com and is being rolled out in store from
18(th) April 2023.

The prevalence of ED disrupts the lives of at least 1 in 5 men globally with
around 22 million men suffering ED in the US and 20 million men in the UK,
France, Italy, Spain and Germany. ED is a growing problem, with around half of
men over the age of 40 experiencing ED and a quarter of men diagnosed with ED
now being under the age of 40. This is being driven by an ageing population,
increased obesity and prevalence of health conditions such as diabetes which
contribute to erectile problems, as well as societal pressures and
"performance anxiety" issues in the case of younger men. There has been little
innovation in ED treatments in over a decade and many patients continue to
suffer dissatisfaction with existing treatments.

Eroxon®, which is fast-acting with minimal side-effects, has the opportunity
to provide an alternative option and significant benefits compared to existing
ED treatments, especially for those patients seeking a spontaneous intercourse
experience as Eroxon® helps users get an erection within 10 minutes.

MED3000 is the first pan-European topical treatment for ED available without
the need of a doctor's prescription and available over the counter.

James Barder, Chief Executive Officer of Futura Medical said: "We are pleased
to confirm that Eroxon is available in the UK from today. This is a
significant milestone for the Company as our distribution partners continue to
increase the availability of Eroxon® across different markets. ED is a
growing problem and we believe that today's announcement will be welcomed by
many men suffering from ED for whom current front-line treatments for ED are
unsuitable."

 

 

ENDS

 

For further information please contact:

 

Futura Medical plc

James Barder, Chief Executive Officer

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com
(mailto:Investor.relations@futuramedical.com)

Tel: +44 (0) 1483 685 670

www.futuramedical.com (http://www.futuramedical.com/)

Nominated Adviser and Sole Broker:

 

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Hollie Vile/ Jonathan Edwards/ Zoe Bolt

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 882 9621

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys® technology. Each DermaSys® formulation is separately patented and
specifically tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and consumer
healthcare markets as appropriate.. Development and commercialisation
strategies are designed to maximise product differentiation and value creation
whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a novel treatment for
erectile dysfunction ("ED") through a unique evaporative mode of action.
Futura has previously conducted an initial Phase 3 study using MED3000 in ED,
referred to as "FM57" which enabled Futura to be granted a CE Mark in 2021. A
second confirmatory Phase 3 clinical study, "FM71" was also conducted to
support Futura's regulatory submission to the FDA with 96 ED patients and
endpoints at 24 weeks, demonstrating that MED3000 presents an effective
clinically proven treatment for ED with a rapid speed of onset and a
favourable benefit versus risk profile ideally suited for an 'Over the
Counter' classification.

Eroxon® is CE marked in Europe and UKCA marked in the UK as a
clinically proven topical treatment for adult men with erectile dysfunction
under the brand Eroxon® with a key claim of "Helps you get an erection within
10 minutes". Eroxon® is the agreed brand name in certain regions such as the
EU whereas MED3000 continues to be the internal code name used by the Company
and also in reference to countries where regulatory approval or commercial
distribution agreements have not yet been achieved. www.eroxon.com
(http://www.eroxon.com)

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(http://www.futuramedical.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFSISLIDLIV